---
title: "BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/286290881.md"
description: "生物科技公司 Legend Biotech 週二報告稱，第一季度收入同比增長 56%，達到 3.051 億美元，受益於與強生旗下的 Janssen 單位合作的癌症治療藥物 Carvykti 的強勁銷售。該季度 Legend 的收入大部分來自與 Janssen 的合作，約為 2.98 億美元。Carvykti 的總銷售額同比增長 62%，達到 5.97 億美元。儘管如此，Legend 在最新季度錄得淨虧損 5430 萬美元，虧損幅度縮小近一半。"
datetime: "2026-05-13T16:05:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286290881.md)
  - [en](https://longbridge.com/en/news/286290881.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286290881.md)
---

# BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment

Drug developer **Legend Biotech Corp.** (LEGN.US) on Tuesday **reported** its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for Carvykti, its cancer treatment that it is commercializing with **Johnson & Johnson’s** (JNJ.US) Janssen unit.

The vast majority of Legend’s revenue for the quarter, about $298 million, came from its Janssen collaboration, which currently sells Carvykti in 18 global markets, including recent launches in Poland, the Czech Republic and Australia. Total Carvykti sales during the quarter grew 62% year-on-year to $597 million.

Legend recorded a net loss of $54.3 million in the latest quarter, narrowing by nearly half from a $101 million loss a year earlier. Its adjusted loss for the quarter narrowed by more than half to $10.5 million from $27 million a year earlier.

Legend Biotech’s New York-listed stock rose 10.5% on Tuesday after the results were published. The stock is up 31% year-to-date.

_By Doug Young_

_To subscribe to Bamboo Works weekly free newsletter, click_ _here_

### 相關股票

- [LEGN.US](https://longbridge.com/zh-HK/quote/LEGN.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [JNJ.US](https://longbridge.com/zh-HK/quote/JNJ.US.md)

## 相關資訊與研究

- [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md)
- [金斯瑞聯營傳奇生物首季虧損降至 5430 萬美元，每股虧損遠遜預期](https://longbridge.com/zh-HK/news/286174837.md)
- [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md)
- [儲局會議記錄顯示 大多數官員警告通脹率若持續高於 2%  需考慮加息](https://longbridge.com/zh-HK/news/287171073.md)
- [瑞銀上調爵士製藥評級：核心業務韌性強勁，新藥 Ziihera 成增長引擎](https://longbridge.com/zh-HK/news/286920691.md)